公开(公告)号：US12082584B2

公开(公告)日：2024-09-10

申请号：US17655536

申请日：2022-03-18

申请人： The Hong Kong University of Science and Technology ,  Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou)

发明人： Peiyuan Qian ,  Ho Yin Chiang ,  Jinping Cheng

IPC分类号： A01N47/12 ,  A01N25/10 ,  A01P15/00 ,  A61L31/16

CPC分类号： A01N47/12 ,  A01N25/10 ,  A01P15/00 ,  A61L31/16 ,  A61L2300/216 ,  A61L2300/404 ,  A01N47/12 ,  A01N25/10

摘要： The subject invention pertains to compositions and methods of coating objects using BOC-butenolide. The invention also relates to compositions and methods for enhancing the performance and longevity of the coated objects with BOC-butenolide, including inhibiting fouling often caused by marine organisms.

公开(公告)号：US20240216589A1

公开(公告)日：2024-07-04

申请号：US18402684

申请日：2024-01-02

申请人： ABBOTT DIABETIS CARE INC.

发明人： Soya J. Gamsey ,  Catherine SNYDER ,  Udo HOSS

IPC分类号： A61L31/16 ,  A61B5/1486 ,  A61L31/04

CPC分类号： A61L31/16 ,  A61B5/14865 ,  A61L31/048 ,  A61L2300/216

摘要： The present disclosure provides a drug delivery composition and a method of controlling a drug delivery rate of an analyte sensor. The drug delivery composition includes a copolymer including a plurality of copolymer chains, where each of the plurality of copolymer chains comprises a backbone including a plurality of hydrophilic units and a plurality of hydrophobic units, a crosslinker, and a therapeutic agent, where the crosslinker crosslinks at least a portion of the hydrophilic units of respective copolymer chains to form charges, and the hydrophobic units of the copolymer interact with the therapeutic agent through the non-polar intermolecular interaction. The drug delivery composition continuously releases the therapeutic agent at a set or predetermined drug delivery rate for a set or predetermined period of time.

公开(公告)号：US12011508B2

公开(公告)日：2024-06-18

申请号：US16965078

申请日：2019-02-01

申请人： Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： Tammy Renee Dugas ,  Cristina Sabliov ,  Carlos Astete

IPC分类号： A61K9/51 ,  A61K31/05 ,  A61K31/366 ,  A61L29/08 ,  A61L29/16 ,  A61M25/10 ,  C08F220/34

CPC分类号： A61K9/5153 ,  A61K9/5138 ,  A61K31/05 ,  A61K31/366 ,  A61L29/085 ,  A61L29/16 ,  A61M25/10 ,  C08F220/34 ,  A61L2300/216 ,  A61L2400/12 ,  A61M2025/105

摘要： In one aspect, the disclosure relates to compositions, methods, and devices pertaining to polymeric nanoparticle compositions (pNP), pNP compositions comprising a therapeutic agent, devices comprising a drug-coated balloon comprising a disclosed pNP comprising a therapeutic agent, and methods for treating peripheral artery disease using the disclosed compositions and devices. In further aspects, the pNP comprises a poly (lactic-co-glycolic) acid possessing a positive charge for firm attachment to the balloon matrix, followed by adhesion to the negatively charged bilayer of the vascular wall. In still further aspects, the therapeutic agent comprises a resveratrol or derivative thereof, a quercetin or derivative thereof, or combinations thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

公开(公告)号：US20240191040A1

公开(公告)日：2024-06-13

申请号：US18583671

申请日：2024-02-21

申请人： PROVIEW-MBD BIOTECH CO., LTD.

发明人： Yu-Chia CHANG ,  Yunn-Kuen CHANG ,  Wen-Yen HUANG ,  Ging-Ho HSIUE ,  Hsieh-Chih TSAI ,  Shuian-Yin LIN ,  Nai-Sheng HSU ,  Tzu-Yu LIN

IPC分类号： C08G81/00 ,  A61K31/337 ,  A61K47/34 ,  A61L31/04 ,  A61L31/06 ,  A61L31/16 ,  C08L71/02

CPC分类号： C08G81/00 ,  A61K31/337 ,  A61K47/34 ,  A61L31/041 ,  A61L31/06 ,  A61L31/16 ,  C08L71/02 ,  A61L2300/216 ,  A61L2300/416 ,  A61L2300/424

摘要： Synthetic amino acid-modified polymers and methods of making the same and using the same are disclosed. The synthetic amino acid-modified polymers possess distinct thermosensitive, improved water-erosion resistant, and enhanced mechanical properties, and are suitable of reducing or preventing formation of postoperative tissue adhesions. Additionally, the amino acid-modified polymers can also be used as a vector to deliver pharmaceutically active agents.

公开(公告)号：US11939432B2

公开(公告)日：2024-03-26

申请号：US17239133

申请日：2021-04-23

申请人： PROVIEW-MBD BIOTECH CO., LTD.

发明人： Yu-Chia Chang ,  Yunn-Kuen Chang ,  Wen-Yen Huang ,  Ging-Ho Hsiue ,  Hsieh-Chih Tsai ,  Shuian-Yin Lin ,  Nai-Sheng Hsu ,  Tzu-Yu Lin

IPC分类号： C08G81/00 ,  A61K31/337 ,  A61K47/34 ,  A61L31/04 ,  A61L31/06 ,  A61L31/16 ,  C08L71/02

CPC分类号： C08G81/00 ,  A61K31/337 ,  A61K47/34 ,  A61L31/041 ,  A61L31/06 ,  A61L31/16 ,  C08L71/02 ,  A61L2300/216 ,  A61L2300/416 ,  A61L2300/424

摘要： Synthetic amino acid-modified polymers and methods of making the same and using the same are disclosed. The synthetic amino acid-modified polymers possess distinct thermosensitive, improved water-erosion resistant, and enhanced mechanical properties, and are suitable of reducing or preventing formation of postoperative tissue adhesions. Additionally, the amino acid-modified polymers can also be used as a vector to deliver pharmaceutically active agents.

公开(公告)号：US11938250B2

公开(公告)日：2024-03-26

申请号：US16272808

申请日：2019-02-11

申请人： Surmodics, Inc.

发明人： David E. Babcock ,  Sean Lundquist ,  Gary Opperman ,  Adriyn Torguson ,  Tim Jentz

IPC分类号： A61L29/08 ,  A61K31/7024 ,  A61L15/44 ,  A61L27/34 ,  A61L27/54 ,  A61L29/06 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  G01N33/543

CPC分类号： A61L29/085 ,  A61K31/7024 ,  A61L15/44 ,  A61L27/34 ,  A61L27/54 ,  A61L29/06 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  G01N33/54393 ,  A61L2300/216 ,  A61L2300/418 ,  A61L2300/42 ,  A61L2400/04 ,  A61L2400/18 ,  A61L2420/02 ,  A61L2420/08

摘要： Embodiments of the disclosure include coatings comprising an oligomerized polyphenol layer. The oligomerized polyphenol layer can be used as an intermediate coated layer on a medical device that hydrogen bonds to a synthetic or natural polymer, which in turn can be used as a top coat or further associated with another coated layer. The multilayered coatings can provide properties such as hemocompatibility or lubricity. In other embodiments, the oligomerized polyphenol layer is used on a medical device as a hemostatic layer configured to contact blood and promote coagulation. The oligomerized polyphenol layer can also be used on the inner surface (e.g., inner diameter) of a medical device to prevent bacterial adherence. The oligomerized polyphenol layer can also be used on the surface of a in vitro diagnostic article, or a cell culture device to, promote adsorption of a biological molecule.

公开(公告)号：US11911476B2

公开(公告)日：2024-02-27

申请号：US16634137

申请日：2018-07-25

申请人： PK MED SAS

发明人： Philippe Pouletty ,  Frédérique Guillamot

IPC分类号： A61K47/34 ,  B29C48/00 ,  A61K31/485 ,  A61K38/47 ,  A61L17/12 ,  A61L24/00 ,  A61L24/04 ,  A61L27/18 ,  A61L27/54 ,  A61L31/06 ,  A61L31/16 ,  C07K16/24 ,  B29K67/00 ,  B29K105/00

CPC分类号： A61K47/34 ,  A61K31/485 ,  A61K38/47 ,  A61L17/12 ,  A61L24/0015 ,  A61L24/046 ,  A61L27/18 ,  A61L27/54 ,  A61L31/06 ,  A61L31/16 ,  B29C48/022 ,  C07K16/241 ,  A61L2300/216 ,  A61L2300/254 ,  B29K2067/043 ,  B29K2067/046 ,  B29K2105/0035 ,  B29K2105/0085

摘要： The present invention relates to process for preparing a drug delivery composition comprising the steps of a) preparing a masterbatch comprising a drug and a first polymer by (i) extruding the first polymer, wherein said first polymer has a melting temperature below 140° C.; and (ii) introducing the drug during extrusion of the first polymer, with a drug content between 0.1% and 90%, based on the total weight of the masterbatch; and b) introducing the masterbatch in a polymer-based matrix during production of the drug delivery composition, wherein step a) is performed at a temperature at which the first polymer is in a partially or totally molten state, and step b) is performed at a temperature at which both the first polymer and at least a polymer of the polymer-based matrix are in a partially or totally molten state.

公开(公告)号：US20240009107A1

公开(公告)日：2024-01-11

申请号：US18036471

申请日：2021-11-05

申请人： BLOOMAGE BIOTECH (TIANJIN) CO., LTD. ,  BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED

发明人： Yuling WANG ,  Xueping GUO ,  Huixia LV ,  Liping QIAO ,  Shujing REN ,  Ximing WEN ,  Xia LI ,  Jing WANG ,  Feng GENG

IPC分类号： A61K8/73 ,  A61Q19/00 ,  A61K31/195 ,  A61K31/122 ,  A61K47/36 ,  A61K8/44 ,  A61K8/35 ,  A61L26/00

CPC分类号： A61K8/735 ,  A61Q19/00 ,  A61K31/195 ,  A61K31/122 ,  A61K47/36 ,  A61K8/44 ,  A61K8/35 ,  A61L26/0023 ,  A61L26/0066 ,  A61K2800/10 ,  A61L2300/214 ,  A61L2300/216

摘要： Disclosed are a hyaluronic acid composition having permeation-promoting effects, a preparation method thereof and the use thereof. Provided is a hyaluronic acid composition, comprising: hyaluronic acid or a salt thereof, an acetylated hyaluronic acid or a salt thereof, and a hydrolyzed hyaluronic acid or a salt thereof. The hyaluronic acid composition of the present application has a small addition amount, can effectively facilitate the absorption of other active ingredients in a formula to achieve synergistic effects, has a small particle size, is uniform, has a fast dissolution rate, has an excellent absorption speed in a product, and is superior to hyaluronic acid treated by means of simple mixing in improving skin hydration. Compared with traditional penetration promoters, the hyaluronic acid composition of the present application causes no damage to the skin and is safe.

公开(公告)号：US20180050131A1

公开(公告)日：2018-02-22

申请号：US15663221

申请日：2017-07-28

申请人： Washington State University

发明人： Susmita Bose ,  Amit Bandyopadhyay ,  Dishary Banerjee ,  Naboneeta Sarkar

IPC分类号： A61L27/54 ,  A61L27/58 ,  A61L27/12 ,  A61L27/56 ,  A61L27/34 ,  A61L27/18 ,  A61L27/44 ,  B33Y10/00 ,  B33Y80/00 ,  A61M31/00

CPC分类号： A61L27/54 ,  A61L27/12 ,  A61L27/18 ,  A61L27/34 ,  A61L27/44 ,  A61L27/56 ,  A61L27/58 ,  A61L2300/216 ,  A61L2300/416 ,  A61L2430/02 ,  A61M31/002 ,  A61M2205/04 ,  A61M2207/10 ,  A61M2210/02 ,  B28B1/001 ,  B28B11/04 ,  B33Y10/00 ,  B33Y80/00 ,  C08L67/04

摘要： Implantable medicine delivery systems, devices, and associated methods are disclosed herein. In one embodiment, a method of enhancing bone regeneration in a human or animal body includes implanting a three-dimensional scaffold in the human or animal body. The three-dimensional scaffold is constructed from a porous ceramic material, a ceramic-polymer composite of a biodegradable ceramic material and a polymer, or a ceramic-polymer-metal composite of a biodegradable ceramic material, a polymer, and a metal and embedded with curcumin in the porous ceramic material, the curcumin at least partially coating an exterior surface of the porous ceramic material. The method also includes directly and controllably releasing the embedded curcumin into a circulatory system of the human or animal body according to a release profile, thereby achieving enhanced bone regeneration in the human or animal body.

公开(公告)号：US20170360991A1

公开(公告)日：2017-12-21

申请号：US15125668

申请日：2015-03-13

申请人： W. L. GORE & ASSOCIATES, INC.

发明人： Robert L. Cleek ,  Paul D. DRUMHELLER ,  Theresa A. HOLLAND ,  Todd J. JOHNSON

IPC分类号： A61L27/54 ,  A61K31/727 ,  A61L31/10 ,  A61L29/16 ,  A61L33/04 ,  A61F2/07 ,  A61L31/16 ,  A61L29/08

CPC分类号： A61L27/54 ,  A61F2/07 ,  A61F2/915 ,  A61F2002/91575 ,  A61K31/337 ,  A61K31/436 ,  A61K31/727 ,  A61K45/06 ,  A61L27/28 ,  A61L29/08 ,  A61L29/085 ,  A61L29/16 ,  A61L31/048 ,  A61L31/08 ,  A61L31/10 ,  A61L31/16 ,  A61L33/0035 ,  A61L33/0076 ,  A61L33/04 ,  A61L33/064 ,  A61L2300/216 ,  A61L2300/416 ,  A61L2300/42 ,  A61L2300/602 ,  A61L2300/606 ,  A61L2300/61 ,  A61L2420/02 ,  A61L2420/06 ,  A61K2300/00

摘要： According to the invention there is provided inter alfa a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.